Brilinta is a lifesaving saver drug, since it. It is used to lower the risk of heart attack or stroke in patients.
Brilinta is a platelet aggregation inhibitor, or an antiplatelet medication. In simple terms, it prevents platelets in the blood from sticking together, or to injured tissues and blood vessels to form unnecessary clots, since they could then could block arteries and disrupt blood flow.
Along with aspirin, Brilinta is given to patients to lower the risk of having heart problems after a heart attack or an episode of chest pain (angina).
Brilinta is available in the form of tablets. The tablets are moderately sized and round in shape. The primary active ingredient in the tablet is Ticagrelor with a chemical formula C23H28F2N6O4S.
With a hepatic mode of metabolism, the compound has a half-life of more than seven hours. It is only meant for oral consumption through the mouth.
Brilinta is a platelet aggregation inhibitor and is used only for specific purposes.
It helps in the smooth flow of blood in the body. It is used for the following purposes:
Ticagrelor, the active ingredient of the tablet, causes some side-effects in the body, and these are likely to be experienced by those using the drug. Below is the comprehensive list of possible side-effects that may occur.
Not all of them occur at once. If any of symptoms are observed, they must be reported to the doctor immediately.
The dosage for Brilinta should be strictly prescribed by the doctor. The doctor may change the strength of the medication based on the complaint of the patient. In most cases the doctors prescribe a loading dose of 80 mg, once every day. This is followed by a maintenance dose twice a day for duration of a year. After a year, the maintenance dose is 60 mg, twice a day.
Brilinta is to be taken along with aspirin daily. The tablet should be taken as a whole and never crushed or broken. It should be taken orally. It can be taken with or without food, but for best results, it should be taken at a fixed time every day.
Ticagrelor binds to P2Y12 subtypes of Adenosine diphosphate (ADP) receptors. Ticagrelor is not like the other antiplatelet drugs. The binding site of Ticagrelor is different from ADP. It does not bind to the active site of the enzyme ADP to disrupt the action. This makes Ticagrelor an allosteric antagonist and therefore, the blockage is reversible.
When the action of ADP is deactivated, the blood flow is smooth in the arteries. The platelets, which form a major component of the blood, do not assemble or cluster together forming a block.
Brilinta must be taken with caution by people with some disorders and diseases. The precautions to be followed while consuming this drug are listed below.
The following are the drugs that have the same compositions and functions as Brilinta, and hence can be used as a substitute. These medications also have antiplatelet activity.
Brilinta interacts with some drugs which may either increase the risk of side-effects or can make the drug less effective. Ticagrelor interacts with the following drugs:
Ans: Yes. No drug interactions have been reported between the two drugs.
Ans: No. Brilinta is an active drug. It is not classified as a prodrug.
Ans: Yes. Brilinta is a generic medicine.
Ans: Brilinta is an antiplatelet drug. Antiplatelet drugs are also described as blood thinners.
Ans: Lowering blood pressure is a reported side effect with usage of Brilinta. In case you experience it, you should approach the doctor immediately.
Ans: No. Hair loss has not been reported as a side effect of Brilinta. If you experience abnormal hair loss, do approach your doctor immediately.
Disclaimer : Docprime doesn’t endorse or take any guarantee of the accuracy or completeness of information provided under this article and these are the views strictly of the writer. Docprime shall not be held responsible for any aspect of healthcare services administered with the information provided on this article.